Poretsky L, Glover B, Laumas V, Kalin M, Dunaif A
Department of Medicine, Mount Sinai School of Medicine, City University of New York, New York 10029.
Endocrinology. 1988 Feb;122(2):581-5. doi: 10.1210/endo-122-2-581.
We randomized 32 cycling female Sprague-Dawley rats (82 days old) into experimental and control groups (16 animals/group). Hyperinsulinemia was induced and maintained for 22 days in the experimental group with NPH human insulin (Novolin, Squibb-Novo, Princeton, NJ) as previously described. Controls received an identical volume of vehicle. Fifteen minutes before death, each rat received a sc injection of 100 ng synthetic GnRH (Factrel, Ayerst Laboratories, New York, NY). The mean serum insulin level was significantly higher in the insulin-treated group than in the control group (165 +/- 57 vs. 49 +/- 9 microU/ml; P less than 0.05). The mean final weight also was significantly higher in the insulin-treated group (283 +/- 4 vs. 242 +/- 7 g; P less than 0.001). There were no significant differences in mean final serum levels of testosterone, estradiol, estrone, or androstenedione or in GnRH-stimulated serum levels of LH or FSH. The androstenedione to estrone ratio, however, was significantly lower in the insulin-treated group (2.5 +/- 0.3 vs. 3.4 +/- 0.2; P less than 0.01), suggesting that aromatase activity increased with hyperinsulinemia. Specific [125I]insulin binding to ovarian tissue homogenates was lower in the insulin-treated group (1.7 +/- 0.1% vs. 2.6 +/- 0.6%/0.2 mg protein; P greater than 0.05), suggesting that ovarian insulin receptors tended to down-regulate with hyperinsulinemia. Specific [125I]insulin-like growth factor I [( 125I]IGF-I) binding to ovarian tissue homogenates, in contrast, was significantly higher in the insulin-treated group (13.3 +/- 1.4% vs. 7.2 +/- 0.6%/0.2 mg protein; P less than 0.05), suggesting that ovarian IGF receptors up-regulated with hyperinsulinemia. The affinity of neither [125I]insulin binding nor that of [125I]IGF-I binding changed significantly, with the 50% inhibition point remaining between 2.0 and 5.0 ng/ml for each peptide in both groups. We conclude that hyperinsulinemia increases ovarian [125I]IGF-I binding and stimulates aromatase activity in the rat. These phenomena, if also true in women, could be important factors contributing to the ovarian hyperstimulation observed in various hyperinsulinemic states.
我们将32只雌性斯普拉格 - 道利大鼠(82日龄)随机分为实验组和对照组(每组16只动物)。如前所述,实验组用NPH人胰岛素(诺和灵,施贵宝 - 诺和诺德公司,新泽西州普林斯顿)诱导并维持高胰岛素血症22天。对照组注射相同体积的溶媒。在处死前15分钟,每只大鼠皮下注射100 ng合成促性腺激素释放激素(Factrel,阿耶斯特实验室,纽约)。胰岛素治疗组的平均血清胰岛素水平显著高于对照组(165±57对49±9微单位/毫升;P<0.05)。胰岛素治疗组的平均最终体重也显著更高(283±4对242±7克;P<0.001)。睾酮、雌二醇、雌酮或雄烯二酮的平均最终血清水平以及促性腺激素释放激素刺激后的促黄体生成素或促卵泡生成素的血清水平在两组之间无显著差异。然而,胰岛素治疗组的雄烯二酮与雌酮的比值显著更低(2.5±0.3对3.4±0.2;P<0.01),这表明芳香化酶活性随高胰岛素血症而增加。胰岛素治疗组中与卵巢组织匀浆特异性结合的[125I]胰岛素较低(1.7±0.1%对2.6±0.6%/0.2毫克蛋白质;P>0.05),这表明卵巢胰岛素受体在高胰岛素血症时倾向于下调。相比之下,胰岛素治疗组中与卵巢组织匀浆特异性结合的[125I]胰岛素样生长因子I([125I]IGF - I)显著更高(13.3±1.4%对7.2±0.6%/0.2毫克蛋白质;P<0.05),这表明卵巢IGF受体在高胰岛素血症时上调。[125I]胰岛素结合和[125I]IGF - I结合的亲和力均未显著改变,两组中每种肽的50%抑制点均保持在2.0至5.0纳克/毫升之间。我们得出结论,高胰岛素血症增加大鼠卵巢[125I]IGF - I结合并刺激芳香化酶活性。如果这些现象在女性中也成立,可能是导致各种高胰岛素血症状态下观察到的卵巢过度刺激的重要因素。